Menu

Report Library

All Reports

Q4 2011 BMT Outlook Report

October 04, 2011

Our Q3 2011 report detailed several significant catalysts that resulted in double-digit stock price changes, details of which can be found in the table on Page 2 of this report.

Our Q4 2011 report covers a number of catalysts from 16 drugs and two devices. Additionally, we have included comprehensive calendars through December 2011 from our sister product, CatalystTracker, of Large Impact catalysts in the drug, device/diagnostic and natural resource areas.

If you would like a copy of the calendars in Excel, please email clientservices@pharmaintel.informa.com or contact your sales representative.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.

Indications Covered: Acute Lymphoblastic Leukemia (ALL)
Chronic Myelogenous Leukemia (CML)
Diabetes Mellitus, Type II
Diabetic Macular Edema
Lennox-Gastaut Syndrome (LGS)
Multiple Myeloma (MM)
Multiple Sclerosis (MS)
Myelofibrosis (MF)
Non-Hodgkin's Lymphoma (NHL)
Non-Small Cell Lung Cancer (NSCLC)
Parkinson's Disease (PD)
Renal Cell Cancer (RCC)
Stroke Prevention in Atrial Fibrillation (SPAF)
Thrombocytopenia
Thyroid Cancer